U.S. IPO Weekly Recap: CRISPR Biotech Pops 44% As More Names Join The IPO Pipeline
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. Units","tickerSymbol":"NASDAQ NCOOU","url":"https://seekingalpha.com/symbol/NCOOU"},{"@type":"Corporation","name":"Pelican Acquisition II Corporation","tickerSymbol":"Private PLCIU","url":"https://seekingalpha.com/symbol/PLCIU"},{"@type":"Corporation","name":"B&R Technology Merger Corp. Cardiovascular disease biotech Scribe Therapeutics (SCTX) upsized and priced at the high end to raise $129 million at a $273 million market cap.
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪Units","tickerSymbol":"NASDAQ NCOOU","url":"https://seekingalpha.com/symbol/NCOOU"},{"@type":"Corporation","name":"Pelican Acquisition II Corporation","tickerSymbol":"Private PLCIU","url":"https://seekingalpha.com/symbol/PLCIU"},{"@type":"C
- ▪Cardiovascular disease biotech Scribe Therapeutics (SCTX) upsized and priced at the high end to raise $129 million at a $273 million market cap.
Seeking Alpha files mainly under finance. We currently carry 6,340 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"IPO Analysis","item":"https://seekingalpha.com/stock-ideas/ipos"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925530-crispr-biotech-pops-44-percent-more-names-join-ipo-pipeline"},"author":{"@type":"Person","name":"Renaissance Capital IPO…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
